These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
148 related articles for article (PubMed ID: 38980837)
41. Influence of impaired glucose tolerance alone and combined with metabolic syndrome on long-term risk of cardiovascular events and mortality. Chen F; He Y; Wang J; Yu L; Gong Q; Chen Y; An Y; He S; Li G; Zhang B J Diabetes; 2024 Aug; 16(8):e13598. PubMed ID: 39155699 [TBL] [Abstract][Full Text] [Related]
42. Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance: the STOP-NIDDM trial. Chiasson JL; Josse RG; Gomis R; Hanefeld M; Karasik A; Laakso M; JAMA; 2003 Jul; 290(4):486-94. PubMed ID: 12876091 [TBL] [Abstract][Full Text] [Related]
43. Association of the magnitude of weight loss and changes in physical fitness with long-term cardiovascular disease outcomes in overweight or obese people with type 2 diabetes: a post-hoc analysis of the Look AHEAD randomised clinical trial. ; Gregg EW; Jakicic JM; Blackburn G; Bloomquist P; Bray GA; Clark JM; Coday M; Curtis JM; Egan C; Evans M; Foreyt J; Foster G; Hazuda HP; Hill JO; Horton ES; Hubbard VS; Jeffery RW; Johnson KC; Kitabchi AE; Knowler WC; Kriska A; Lang W; Lewis CE; Montez MG; Nathan DM; Neiberg RH; Patricio J; Peters A; Pi-Sunyer X; Pownall H; Redmon B; Regensteiner J; Rejeski J; Ribisl PM; Safford M; Stewart K; Trence D; Wadden TA; Wing RR; Yanovski SZ Lancet Diabetes Endocrinol; 2016 Nov; 4(11):913-921. PubMed ID: 27595918 [TBL] [Abstract][Full Text] [Related]
44. Impaired glucose tolerance, diabetes, and cardiovascular disease risk factor profiles in the elderly. The Honolulu Heart Program. Rodriguez BL; Curb JD; Burchfiel CM; Huang B; Sharp DS; Lu GY; Fujimoto W; Yano K Diabetes Care; 1996 Jun; 19(6):587-90. PubMed ID: 8725856 [TBL] [Abstract][Full Text] [Related]
45. Cardiovascular risk profile in individuals with borderline glycemia: the effect of the 1997 American Diabetes Association diagnostic criteria and the 1998 World Health Organization Provisional Report. Lim SC; Tai ES; Tan BY; Chew SK; Tan CE Diabetes Care; 2000 Mar; 23(3):278-82. PubMed ID: 10868851 [TBL] [Abstract][Full Text] [Related]
46. A randomised trial of the effect and cost-effectiveness of early intensive multifactorial therapy on 5-year cardiovascular outcomes in individuals with screen-detected type 2 diabetes: the Anglo-Danish-Dutch Study of Intensive Treatment in People with Screen-Detected Diabetes in Primary Care (ADDITION-Europe) study. Simmons RK; Borch-Johnsen K; Lauritzen T; Rutten GE; Sandbæk A; van den Donk M; Black JA; Tao L; Wilson EC; Davies MJ; Khunti K; Sharp SJ; Wareham NJ; Griffin SJ Health Technol Assess; 2016 Aug; 20(64):1-86. PubMed ID: 27583404 [TBL] [Abstract][Full Text] [Related]
47. Basal insulin and cardiovascular and other outcomes in dysglycemia. ; Gerstein HC; Bosch J; Dagenais GR; Díaz R; Jung H; Maggioni AP; Pogue J; Probstfield J; Ramachandran A; Riddle MC; Rydén LE; Yusuf S N Engl J Med; 2012 Jul; 367(4):319-28. PubMed ID: 22686416 [TBL] [Abstract][Full Text] [Related]
48. Impaired glucose tolerance is a risk factor for cardiovascular disease, but not impaired fasting glucose. The Funagata Diabetes Study. Tominaga M; Eguchi H; Manaka H; Igarashi K; Kato T; Sekikawa A Diabetes Care; 1999 Jun; 22(6):920-4. PubMed ID: 10372242 [TBL] [Abstract][Full Text] [Related]
49. Diabetes, plasma insulin, and cardiovascular disease: subgroup analysis from the Department of Veterans Affairs high-density lipoprotein intervention trial (VA-HIT). Rubins HB; Robins SJ; Collins D; Nelson DB; Elam MB; Schaefer EJ; Faas FH; Anderson JW Arch Intern Med; 2002 Dec 9-23; 162(22):2597-604. PubMed ID: 12456232 [TBL] [Abstract][Full Text] [Related]
50. Gender differences in screening for glucose perturbations, cardiovascular risk factor management and prognosis in patients with dysglycaemia and coronary artery disease: results from the ESC-EORP EUROASPIRE surveys. Ferrannini G; De Bacquer D; Vynckier P; De Backer G; Gyberg V; Kotseva K; Mellbin L; Norhammar A; Tuomilehto J; Wood D; Rydén L; Cardiovasc Diabetol; 2021 Feb; 20(1):38. PubMed ID: 33573665 [TBL] [Abstract][Full Text] [Related]
51. Early lifestyle intervention in patients with non-insulin-dependent diabetes mellitus and impaired glucose tolerance. Uusitupa MI Ann Med; 1996 Oct; 28(5):445-9. PubMed ID: 8949977 [TBL] [Abstract][Full Text] [Related]
52. Effect of a long-term oral l-arginine supplementation on glucose metabolism: a randomized, double-blind, placebo-controlled trial. Monti LD; Setola E; Lucotti PC; Marrocco-Trischitta MM; Comola M; Galluccio E; Poggi A; Mammì S; Catapano AL; Comi G; Chiesa R; Bosi E; Piatti PM Diabetes Obes Metab; 2012 Oct; 14(10):893-900. PubMed ID: 22553931 [TBL] [Abstract][Full Text] [Related]
53. Risk of chronic kidney disease in young adults with impaired glucose tolerance/impaired fasting glucose: a retrospective cohort study using electronic primary care records. Jadhakhan F; Marshall T; Ryan R; Gill P BMC Nephrol; 2018 Feb; 19(1):42. PubMed ID: 29482513 [TBL] [Abstract][Full Text] [Related]
54. Long-term effects of lowering postprandial glucose level on cardiovascular outcomes in early-stage diabetic patients with coronary artery disease: 10-year post-trial follow-up analysis of the DIANA study. Kataoka Y; Yasuda S; Asaumi Y; Honda S; Noguchi T; Miyamoto Y; Sase K; Iwahashi N; Kawamura T; Kosuge M; Kimura K; Takamisawa I; Iwanaga Y; Miyazaki S J Diabetes Complications; 2023 May; 37(5):108469. PubMed ID: 36996727 [TBL] [Abstract][Full Text] [Related]
55. Identical anthropometric characteristics of impaired fasting glucose combined with impaired glucose tolerance and newly diagnosed type 2 diabetes: anthropometric indicators to predict hyperglycaemia in a community-based prospective cohort study in southwest China. Zhang F; Wan Q; Cao H; Tang L; Li D; Lü Q; Yan Z; Li J; Yang Q; Zhang Y; Tong N BMJ Open; 2018 May; 8(5):e019735. PubMed ID: 29743321 [TBL] [Abstract][Full Text] [Related]
56. Elevated 1-h post-load plasma glucose levels in subjects with normal glucose tolerance are associated with a pro-atherogenic lipid profile. Andreozzi F; Mannino GC; Perticone M; Perticone F; Sesti G Atherosclerosis; 2017 Jan; 256():15-20. PubMed ID: 27940375 [TBL] [Abstract][Full Text] [Related]
57. Diabetes, pre-diabetes and associated risks on Minnesota code-indicated major electrocardiogram abnormality among Chinese: a cross-sectional diabetic study in Fujian province, southeast China. Lin L; Chen G; Zou X; Zhao J; Zhu F; Tu M; Xu S; Lin W; Yang S; Zhang Y; Lin M; Chen N; Huang H; Liang J; Li L; Yao J Obes Rev; 2009 Jul; 10(4):420-30. PubMed ID: 19460110 [TBL] [Abstract][Full Text] [Related]
58. Does diabetes prevention translate into reduced long-term vascular complications of diabetes? Nathan DM; Bennett PH; Crandall JP; Edelstein SL; Goldberg RB; Kahn SE; Knowler WC; Mather KJ; Mudaliar S; Orchard TJ; Temprosa M; White NH; Diabetologia; 2019 Aug; 62(8):1319-1328. PubMed ID: 31270584 [TBL] [Abstract][Full Text] [Related]
59. Impaired glucose tolerance, impaired fasting glycaemia and cardiovascular risk. Sanusi H Acta Med Indones; 2004; 36(1):36-41. PubMed ID: 15673935 [TBL] [Abstract][Full Text] [Related]
60. Randomised controlled trial evaluating the effectiveness of behavioural interventions to modify cardiovascular risk factors in men and women with impaired glucose tolerance: outcomes at 6 months. Oldroyd JC; Unwin NC; White M; Imrie K; Mathers JC; Alberti KG Diabetes Res Clin Pract; 2001 Apr; 52(1):29-43. PubMed ID: 11182214 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]